Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Raw Materials: 2013-2018

Historic Raw Materials for Theravance Biopharma (TBPH) over the last 5 years, with Sep 2018 value amounting to $10.8 million.

  • Theravance Biopharma's Raw Materials rose 8.41% to $10.8 million in Q3 2018 from the same period last year, while for Sep 2018 it was $10.8 million, marking a year-over-year increase of 8.41%. This contributed to the annual value of $11.7 million for FY2017, which is 93.32% up from last year.
  • Per Theravance Biopharma's latest filing, its Raw Materials stood at $10.8 million for Q3 2018, which was up 1.95% from $10.6 million recorded in Q2 2018.
  • In the past 5 years, Theravance Biopharma's Raw Materials ranged from a high of $11.7 million in Q4 2017 and a low of $4.0 million during Q1 2014.
  • For the 3-year period, Theravance Biopharma's Raw Materials averaged around $8.4 million, with its median value being $7.4 million (2017).
  • In the last 5 years, Theravance Biopharma's Raw Materials decreased by 21.94% in 2016 and then skyrocketed by 93.32% in 2017.
  • Over the past 5 years, Theravance Biopharma's Raw Materials (Quarterly) stood at $6.8 million in 2014, then climbed by 0.57% to $6.9 million in 2015, then dropped by 11.68% to $6.1 million in 2016, then surged by 93.32% to $11.7 million in 2017, then grew by 8.41% to $10.8 million in 2018.
  • Its Raw Materials stands at $10.8 million for Q3 2018, versus $10.6 million for Q2 2018 and $10.6 million for Q1 2018.